Alessandro Di Federico

34PUBLICATIONS
276CO-AUTHORS
Molecular targetsPredictive and prognostic markersInnate immunityCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (34)

|Jul 15, 2026
Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.

|Jul 14, 2026
Clinical Significance of EGFR Amplification in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer Receiving First-line Osimertinib.

|May 18, 2026
Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco.

|Sep 04, 2025
Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8+ and PD-1+ Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk Factors.

Joao V Alessi, James R Lindsay, Anita Giobbie-Hurder

|Aug 27, 2025
First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC.

Federica Pecci, Hui Li, Alessandro Di Federico

|Jun 13, 2025
Efficacy and Safety of TROP-2-Targeting Antibody-Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient Data.

Sara Stumpo, Andrea Carlini, Francesco Mantuano

Pageof 6

Frequent Collaborators

15 joint publications

Biagio Ricciuti

14 joint publications

Andrea De Giglio

13 joint publications

Mark Magdi Awad

11 joint publications

Joao Victor Alessi